Geeta Ganesh, MD
Neurology · Louisville, KYNPI 1831358506
Payments from drug & device makers
Across 497 payments — averaging $1539.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$671K
- Roche Products Limited$57K
- Novartis$29K
- Biogen$2K
- EMD Serono, Inc.$1K
- AstraZeneca$899
- plus $3K from 26 others
What the payments were for
- Consulting fees$1,80020%
- Speaking & faculty fees$1502%
- Food & beverage$6,15167%
- Education$6617%
- Gifts$4455%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 78 | $671,070 |
| Roche Products Limited | 82 | $57,174 |
| Novartis | 63 | $29,330 |
| Biogen | 40 | $2,389 |
| EMD Serono, Inc. | 56 | $1,226 |
| AstraZeneca | 16 | $899 |
| Vanda Pharmaceuticals Inc. | 7 | $786 |
| Genentech USA, Inc. | 28 | $515 |
| TG Therapeutics, Inc. | 7 | $232 |
| CSL Behring | 11 | $198 |
| Amgen(2 entities) | 13 | $193 |
| AbbVie | 21 | $171 |
| Acorda Therapeutics, Inc | 15 | $165 |
| Grifols USA, LLC | 7 | $136 |
| Teva Pharmaceuticals USA, Inc. | 22 | $120 |
| Bristol Myers Squibb | 3 | $54 |
| Johnson & Johnson | 3 | $49 |
| Mallinckrodt Enterprises LLC | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Genentech, Inc. | 2 | $48 |
| Avanir Pharmaceuticals, Inc. | 3 | $36 |
| Banner Life Sciences, LLC | 2 | $30 |
| Lilly USA, LLC | 2 | $29 |
| UCB, Inc. | 1 | $29 |
| Assertio Therapeutics, Inc. | 2 | $27 |
| Sobi, Inc | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Advanced Respiratory, Inc | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Mallinckrodt Hospital Products Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$765,117 in reported general payments places this provider in the 95th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 125 | $1,269,627 |
| MavencladCladribine | 12 | $929,992 |
| MayzentSiponimod | 78 | $929,222 |
| TecfideraDimethyl Fumarate | 37 | $373,953 |
| VumerityDiroximel Fumarate | 40 | $347,882 |
| CopaxoneGlatiramer Acetate | 62 | $344,997 |
| Avonex (4 Pack)Interferon Beta-1a | 38 | $312,029 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 36 | $311,557 |
| AubagioTeriflunomide | 29 | $273,227 |
| Glatiramer Acetate | 76 | $195,974 |
| EnspryngSatralizumab-Mwge | 11 | $193,041 |
| ZeposiaOzanimod Hydrochloride | 17 | $168,906 |
| GilenyaFingolimod Hcl | 16 | $162,192 |
| Teriflunomide | 133 | $128,427 |
| GlatopaGlatiramer Acetate | 60 | $127,569 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMayzent, Gilenya | $29,330 | $1,091,41494 claims |
| BiogenTecfidera, Vumerity, Avonex (4 Pack) | $2,389 | $1,033,865115 claims |
| EMD Serono, Inc.Mavenclad | $1,226 | $929,99212 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $120 | $344,99762 claims |
| SanofiAubagio | $671,070 | $273,22729 claims |
| Genentech USA, Inc.Enspryng | $515 | $193,04111 claims |
| AbbVieUbrelvy | $171 | $12,36412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 neurology providers in Kentucky.
Other neurology in Louisville
- Irene LitvanLouisville$2.7M
- Jenny FengLouisville$2M
- Peter HederaLouisville$422K
- Gregory CooperLouisville$291K
- Brian PlatoLouisville$267K
- Kristi NordLouisville$217K
- Michael SweeneyLouisville$201K
- Angela HardwickLouisville$187K
- Jeffrey FrankLouisville$181K
- Kaylyn SinicropeLouisville$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.